A small-caliber artificial blood vessel with dual anti-calcification properties and a preparation method thereof

By combining electrospinning technology and physical cross-linking methods in artificial vascular scaffolds, anti-calcification functional layer containing decellularized matrix powder and cathepsin S inhibitors, and dual anti-calcification small-diameter artificial blood vessels loaded with baicalin, the solution was solved The problem of artificial vascular calcification significantly improves the tensile resistance and biocompatibility of blood vessels.

CN116726253BActive Publication Date: 2024-12-03TIANJIN UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202310650201.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03
Estimated Expiration
2043-06-02

AI Technical Summary

Technical Problem

Existing artificial blood vessels are prone to calcification after long-term implantation, resulting in sclerosis of the blood vessel wall and reduced blood flow compliance, which in turn causes problems such as myocardial ischemia and ventricular hypertrophy. The existing technology is difficult to effectively inhibit calcification.

Method used

Using a dual anti-calcification small-diameter artificial vascular scaffold, an anti-calcification functional layer containing decellularized matrix powder and cathepsin S inhibitor was prepared by electrospinning, and physically cross-linked loaded baicalin throughout the scaffold, combining structural support functions. layer to enhance mechanical properties.

Benefits of technology

Effectively inhibit the occurrence of vascular calcification, through the hydrogen bond interaction between baicalin and proteoamide carbonyl and the binding of the decellularized matrix, the calcium ion deposition site is reduced, the risk of calcification is significantly reduced, and the anti-tension performance of blood vessels is improved and the biological properties of blood vessels are improved. Compatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116726253B_ABST
    Figure CN116726253B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of artificial blood vessel technology, and specifically relates to a small-caliber artificial blood vessel with dual anti-calcification and a preparation method thereof, which includes, from the inside to the outside, an anti-calcification functional layer along the inner diameter direction of the blood vessel; the anti-calcification functional layer is prepared by electrostatic spinning a solution containing a basic material, wherein the solution containing the basic material contains acellular matrix powder and a cathepsin S inhibitor; the structural support functional layer is prepared by electrostatic spinning a solution containing a basic material; the anti-calcification functional layer and the structural support functional layer are both loaded with baicalin by physical cross-linking. The present invention prepares an artificial blood vessel stent containing acellular matrix, adds a cathepsin S inhibitor in the process of preparing the stent, and physically cross-links the stent with baicalin, which has the effect of achieving dual anti-calcification.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of artificial blood vessels, and in particular relates to a small-caliber artificial blood vessel with dual anti-calcification properties and a preparation method thereof. Background Art

[0002] Vascular injury is a common clinical disease, including acute injuries caused by natural disasters, traffic accidents, wars, etc., and chronic cardiovascular diseases caused by coronary heart disease, atherosclerosis, etc. Vascular transplantation is one of the important means of treating cardiovascular diseases clinically. Clinically, vascular calcification is a common pathological process that can reduce the smoothness of the vascular wall, make the blood vessels brittle and hard, and reduce the compliance of blood flow. It leads to myocardial ischemia, ventricular hypertrophy, thrombosis, atherosclerosis, stroke, etc. Similarly, calcification is the main factor for the failure of long-term implantation of artificial blood vessels, which is manifested as the deposition of hydroxyapatite on the vascular wall. The reasons for its formation are very complex and may be related to the material degradation rate, compliance and degradation products, and may also be closely related to the body's metabolism, development and inflammatory response. Therefore, the development of a replaceable long-term anti-calcification small-caliber artificial vascular stent has important research and clinical significance for the treatment of cardiovascular diseases. Summary of the invention

[0003] In order to solve the above technical problems, the present invention provides a small-caliber artificial blood vessel with dual anti-calcification and a preparation method thereof. The present invention prepares an artificial blood vessel stent containing a cell-free matrix, adds a cathepsin S (cat S) inhibitor during the preparation of the stent, and physically cross-links the stent with baicalin, thereby achieving a dual anti-calcification effect.

[0004] The present invention is specifically achieved through the following technical solutions.

[0005] A small-caliber artificial blood vessel with dual anti-calcification properties, which includes, from inside to outside, an anti-calcification functional layer and a structural support functional layer along the inner diameter direction of the blood vessel;

[0006] The anti-calcification functional layer is prepared by electrospinning a solution containing a basic material, wherein the solution containing the basic material contains acellular matrix powder and a cathepsin S inhibitor;

[0007] The structural support functional layer is prepared by electrostatically spinning a solution containing a basic material;

[0008] The anti-calcification functional layer and the structural support functional layer are both loaded with baicalin by means of physical cross-linking.

[0009] Furthermore, the base material in the first solution containing the base material and the base material in the second solution containing the base material are both poly-L-lactide-caprolactone.

[0010] The method for preparing the above-mentioned dual anti-calcification small-caliber artificial blood vessel comprises the following steps:

[0011] S1. Solution preparation

[0012] The basic material is dissolved in a solvent to prepare system one; the decellularized matrix powder is added to system one to prepare system two; the cathepsin S inhibitor is added to system two to prepare solution one containing the basic material;

[0013] Adding baicalin to the solvent to prepare system three;

[0014] S2. Preparation of artificial vascular stent

[0015] The solution containing the basic material is electrospinned to prepare the inner layer of the vascular stent; the inner layer of the vascular stent is placed in the system three, shaken, and physically cross-linked to prepare the anti-calcification functional layer;

[0016] On the outside of the anti-calcification functional layer, the system one is used to prepare the outer layer of the vascular stent by electrospinning to obtain a stent precursor, and the stent precursor is placed in the system three, shaken, and physically cross-linked to prepare a structural support functional layer, thereby completing the preparation of the dual anti-calcification small-caliber artificial blood vessel.

[0017] Further, in system 1, the solvent is hexafluoroisopropanol, and the mass / volume concentration of the base material is 12%;

[0018] In system 2, the mass / volume concentration of the decellularized matrix powder was 0.5-5%;

[0019] In the solution 1 containing the base material, the concentration of the cathepsin S inhibitor is 50-500 mg / mL;

[0020] In system three, the solvent is hexafluoroisopropanol, and the concentration of baicalin is 0.5-5.0 mg / mL.

[0021] Furthermore, when preparing the inner layer of the vascular stent, the electrospinning conditions are: the flow rate of the inner layer of the vascular stent is 0.1-4.0 mL / h, the voltage is 6-15 kV, and the receiving distance is 8-20 cm.

[0022] Furthermore, when preparing the outer layer of the vascular stent, the electrospinning conditions are: the outer layer flow rate of the vascular stent is 1.0-6.0 mL / h, the voltage is 8-15 kV, and the receiving distance is 10-20 cm.

[0023] Furthermore, the inner layer of the vascular stent is placed in system three, and the physical cross-linking time is 1-2 days.

[0024] Furthermore, the scaffold precursor is placed in system three, and the physical cross-linking time is 1-2 days.

[0025] Furthermore, after the structural support functional layer is prepared, it is placed in a vacuum drying oven for 24-48 hours.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] The double anti-calcification small-caliber artificial blood vessel stent provided by the present invention is loaded with anti-calcification drug components and decellularized extracellular matrix powder (Decellularized extracellular matrix, dECM). The stent functions to promote tissue regeneration and inhibit the occurrence of vascular calcification. Natural blood vessels contain active factors that promote cell growth. The natural blood vessel pig thoracic aorta is decellularized to remove immunogenicity, freeze-dried, and ground into powder. The prepared small-caliber artificial blood vessel stent is composed of the basic material poly-L-lactide-caprolactone (PLCL), and its structure is divided into two layers, the inner layer is the anti-calcification functional layer (composite PLCL with decellularized matrix powder, loaded with anti-calcification drug cat S inhibitor to prevent the occurrence of calcification), and the outer layer is the structural support functional layer (composed of simple PLCL, enhancing the mechanical properties of artificial blood vessels, so that it has good tensile resistance). In addition, the entire stent is loaded with baicalin by physical cross-linking, in order to reduce the calcium ion deposition site from the microstructure dimension of the stent and inhibit the occurrence of artificial blood vessel calcification.

[0028] Among them, the cross-linking mechanism of baicalin (BA) may be related to the hydrogen bond interaction mainly formed by the protein amide carbonyl and the phenolic hydroxyl of baicalin. Baicalin can specifically bind to the hydrophobic regions of proline-rich elastin and collagen to form multiple hydrogen bonds, effectively protecting elastin from enzymatic degradation and inhibiting elastin-related calcification (elastin-derived peptides can induce osteogenic transformation of cells and are related to vascular calcification). Baicalin cross-linking of decellularized matrix materials can block calcium phosphate nucleation, inhibit mineral deposition, and effectively inhibit calcification.

[0029] Cathepsin S (cat S) is a cysteine ​​protease that can cut elastin and produce biologically active elastin peptides, thereby promoting cardiovascular inflammation and calcification. Cat S secreted by macrophages can degrade elastin. When the elastin layer is destroyed, it promotes the proliferation of vascular smooth muscle cells (VSMC), which in turn leads to the formation and growth of lesions. Elastin degradation products activate VSMC to differentiate into osteoblasts. Elastin fragments cut by cat S promote VSMC osteogenic activity more effectively than randomly cut elastin fragments. The present invention inhibits cat S activity by adding cystatin C (an endogenous inhibitor of cathepsin) to weaken the osteogenic differentiation of VSMC caused by cat S.

[0030] The artificial blood vessel stent product of the present invention effectively inhibits the occurrence of calcification through the dual effects of cross-linking baicalin and loading cat S inhibitor. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Infrared detection of baicalin used in the present invention;

[0032] Figure 2 The deposition of apatite on the surface of the artificial vascular stents prepared in Examples 1-3 and Comparative Example 1 was observed by SEM;

[0033] Figure 3 This is a photo of the on-site sampling of subcutaneous implants in SD rats;

[0034] Figure 4 VonKossa staining was performed on the artificial vascular stents of Example 1 and Comparative Example 2 to observe the calcification. DETAILED DESCRIPTION

[0035] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is further described below in conjunction with specific embodiments and drawings, but the embodiments are not intended to limit the present invention.

[0036] The experimental methods and detection methods described in the following embodiments are conventional methods unless otherwise specified; the reagents and materials are commercially available unless otherwise specified.

[0037] A small-caliber artificial blood vessel with dual anti-calcification properties, which includes, from inside to outside, an anti-calcification functional layer and a structural support functional layer along the inner diameter direction of the blood vessel;

[0038] The anti-calcification functional layer is prepared by electrospinning a solution containing a basic material, wherein the solution containing the basic material contains acellular matrix powder and a cathepsin S inhibitor;

[0039] The structural support functional layer is prepared by electrostatically spinning a solution containing a basic material;

[0040] The anti-calcification functional layer and the structural support functional layer are both loaded with baicalin by means of physical cross-linking.

[0041] More specifically, the stent is loaded with anti-calcification drug components and decellularized extracellular matrix powder (Decellularized extracellular matrix, dECM). The stent functions to promote tissue regeneration and inhibit the occurrence of vascular calcification. Natural blood vessels contain active factors that promote cell growth. The natural blood vessel pig thoracic aorta is decellularized to remove immunogenicity, freeze-dried, and ground into powder. The prepared small-caliber artificial vascular stent is composed of the basic material poly-L-lactide-caprolactone (PLCL), and its structure is divided into two layers, the inner layer is the anti-calcification functional layer (composite PLCL with decellularized matrix powder, loaded with anti-calcification drug cat S inhibitor to prevent the occurrence of calcification), and the outer layer is the structural support functional layer (composed of pure PLCL, enhancing the mechanical properties of artificial blood vessels, so that it has good tensile resistance). In addition, the entire stent is loaded with baicalin by physical cross-linking, in order to reduce the calcium ion deposition site from the microstructure dimension of the stent and inhibit the occurrence of artificial blood vessel calcification. The artificial vascular stent product of the present invention inhibits the occurrence of calcification through the dual effects of cross-linking baicalin and loading cat S inhibitor.

[0042] The present invention selects PLCL, decellularized matrix powder, baicalin, and cat S inhibitor as components of vascular stents. PLCL is a material approved by the FDA for use in medical drugs, which is safe and reliable. Decellularized matrix powder is prepared by decellularizing the thoracic aorta of a pig, completely removing immunogenicity, and grinding it to form a powder. It is derived from natural blood vessels, has good biocompatibility, contains a variety of biological factors that promote the growth of endothelial cells, smooth muscles, and fibroblasts, and can effectively promote the regeneration of artificial vascular tissue. In addition, the decellularized matrix powder is a natural component with good biodegradability, so that the degradation process of blood vessels and tissue regeneration can be matched, and the occurrence of aneurysms is successfully avoided. Baicalin is a natural compound extracted from the medicinal plant Scutellaria baicalensis, a flavonoid substance, in which the phenolic hydroxyl group can form a hydrogen bond interaction with the protein amide carbonyl group; and the flavonoid substance specifically binds to the hydrophobic region of proline-rich elastin and collagen to form multiple hydrogen bonds. It effectively protects elastin from enzymatic degradation (derived peptides from elastin degradation can induce osteogenic transformation of cells and are related to vascular calcification), and further inhibits calcification caused by elastin. The decellularized matrix contains elastin and collagen. After the artificial blood vessels containing the decellularized matrix are cross-linked with baicalin, they can protect the degradation of elastin, thereby reducing the occurrence of calcification. Cathepsin S (cat S) can cut elastin and produce bioactive elastin peptides, thereby promoting cardiovascular inflammation and calcification. Therefore, cat S inhibitors are loaded during the preparation of vascular stents to reduce the cutting of elastin, thereby reducing the occurrence of calcification of vascular stents.

[0043] The present invention will be specifically described below by the following examples.

[0044] Example 1

[0045] A method for preparing a small-caliber artificial blood vessel with dual anti-calcification properties comprises the following steps:

[0046] (1) Preparation of decellularized matrix powder

[0047] The porcine thoracic aorta retrieved from the slaughterhouse was decellularized using a combination of hypertonic and hypotonic solutions, TritonX-100 and bio-enzymes, freeze-dried, ground into powder, and stored at -20°C for later use.

[0048] (2) Preparation of electrospinning solution

[0049] 1) Preparation of PLCL solution: 1.2 g of PLCL material was dissolved in 10 ml of hexafluoroisopropanol (HFIP), and the solution was stirred overnight on a magnetic stirrer to obtain a PLCL solution with a mass / volume concentration of 12%.

[0050] 2) Prepare a solution containing decellularized matrix powder: dissolve the decellularized matrix powder in the solution prepared in 1) to obtain a solution with a mass / volume concentration of 0.5%. Stir the solution on a magnetic stirrer for several hours and set aside.

[0051] 3) Weigh a certain amount of catS inhibitor and dissolve it in 2) to make the final drug concentration 50 mg / mL.

[0052] 4) Preparation of baicalin cross-linking solution: Weigh a certain amount of baicalin powder, dissolve it in hexafluoroisopropanol (HFIP) at a concentration of 0.5 mg / mL, and ultrasonicate for 1 min. This solution is used for physical cross-linking of the stent to prevent calcification.

[0053] (3) Preparation of artificial vascular stent

[0054] By means of electrospinning, a degradable anti-calcification artificial vascular stent loaded with cat S inhibitor and cross-linked with baicalin was prepared. The solution prepared in step 3) was electrospun, and the electrospinning conditions were as follows: the inner layer flow rate of the vascular stent was 0.1 mL / h, the voltage was 6 kV, and the receiving distance was 8 cm; after the inner layer was spun, the blood vessel was placed in a vessel containing baicalin solution of different concentrations together with the stainless steel rod for oscillation physical cross-linking for 1 day. After the cross-linking was completed, the outer layer of the vascular stent was electrospun continuously, and the PLCL solution prepared in step 1) was electrospun, and the outer layer flow rate of the blood vessel was 1.0 mL / h, the voltage was 8 kV, and the receiving distance was 10 cm. The receiver of the tubular stent was a stainless steel rod with a diameter of 2 mm. After the spinning was completed, the tube was removed, and the vascular stent separated from the stainless steel rod was cross-linked again for 1 day. After the cross-linking was completed, the artificial blood vessel was placed in a vacuum drying oven for 24 hours to obtain a double anti-calcification decellular matrix artificial blood vessel loaded with cat S inhibitor cross-linked with baicalin.

[0055] Example 2

[0056] A method for preparing a small-caliber artificial blood vessel with dual anti-calcification properties comprises the following steps:

[0057] (1) Preparation of decellularized matrix powder

[0058] The porcine thoracic aorta retrieved from the slaughterhouse was decellularized using a combination of hypertonic and hypotonic solutions, TritonX-100 and bio-enzymes, freeze-dried, ground into powder, and stored at -20°C for later use.

[0059] (2) Preparation of electrospinning solution

[0060] 1) Preparation of PLCL solution: 1.2 g of PLCL material was dissolved in 10 ml of hexafluoroisopropanol (HFIP), and the solution was stirred overnight on a magnetic stirrer to obtain a PLCL solution with a mass / volume concentration of 12%.

[0061] 2) Prepare a solution containing decellularized matrix powder: dissolve the decellularized matrix powder in the solution prepared in 1) to obtain a solution with a mass / volume concentration of 5%. Stir the solution on a magnetic stirrer for several hours and set aside.

[0062] 3) Weigh a certain amount of catS inhibitor and dissolve it in 2) to make the final drug concentration 500 mg / mL.

[0063] 4) Preparation of baicalin cross-linking solution: Weigh a certain amount of baicalin powder, dissolve it in hexafluoroisopropanol (HFIP) at a concentration of 5.0 mg / mL, and ultrasonicate for 5 minutes. This solution is used for physical cross-linking of the stent to prevent calcification.

[0064] (3) Preparation of artificial vascular stent

[0065] By means of electrospinning, a degradable anti-calcification artificial vascular stent loaded with cat S inhibitor and cross-linked with baicalin was prepared. The solution prepared in step 3) was electrospun, and the electrospinning conditions were as follows: the inner layer flow rate of the vascular stent was 4.0 mL / h, the voltage was 15 kV, and the receiving distance was 20 cm; after the inner layer was spun, the blood vessel was placed in a vessel containing baicalin solution of different concentrations together with the stainless steel rod for oscillation physical cross-linking for 2 days. After the cross-linking was completed, the outer layer of the vascular stent was electrospun continuously, and the PLCL solution prepared in step 1) was electrospun, and the outer layer flow rate of the blood vessel was 6.0 mL / h, the voltage was 15 kV, and the receiving distance was 20 cm. The receiver of the tubular stent was a stainless steel rod with a diameter of 6 mm. After the spinning was completed, the tube was removed, and the vascular stent separated from the stainless steel rod was cross-linked again for 2 days. After the cross-linking was completed, the artificial blood vessel was placed in a vacuum drying oven for 48 hours to obtain a double anti-calcification decellular matrix artificial blood vessel loaded with cat S inhibitor cross-linked with baicalin.

[0066] Example 3

[0067] A method for preparing a small-caliber artificial blood vessel with dual anti-calcification properties comprises the following steps:

[0068] (1) Preparation of decellularized matrix powder

[0069] The porcine thoracic aorta retrieved from the slaughterhouse was decellularized using a combination of hypertonic and hypotonic solutions, TritonX-100 and bio-enzymes, freeze-dried, ground into powder, and stored at -20°C for later use.

[0070] (2) Preparation of electrospinning solution

[0071] 1) Preparation of PLCL solution: 1.2 g of PLCL material was dissolved in 10 ml of hexafluoroisopropanol (HFIP), and the solution was stirred overnight on a magnetic stirrer to obtain a PLCL solution with a mass / volume concentration of 12%.

[0072] 2) Prepare a solution containing decellularized matrix powder: dissolve the decellularized matrix powder in the solution prepared in 1) to obtain a solution with a mass / volume concentration of 1%. Stir the solution on a magnetic stirrer for several hours and set aside.

[0073] 3) Weigh a certain amount of catS inhibitor and dissolve it in 2) to make the final drug concentration 100 mg / mL.

[0074] 4) Preparation of baicalin cross-linking solution: Weigh a certain amount of baicalin powder, dissolve it in hexafluoroisopropanol (HFIP) at a concentration of 1.0 mg / mL, and ultrasonicate for 3 minutes. This solution is used for physical cross-linking of the stent to prevent calcification.

[0075] (3) Preparation of artificial vascular stent

[0076] By means of electrospinning, a degradable anti-calcification artificial vascular stent loaded with cat S inhibitor and cross-linked with baicalin was prepared. The solution prepared in step 3) was electrospun, and the electrospinning conditions were as follows: the inner layer flow rate of the vascular stent was 2.0 mL / h, the voltage was 10 kV, and the receiving distance was 10 cm; after the inner layer was spun, the blood vessel was placed in a vessel containing baicalin solutions of different concentrations together with the stainless steel rod for oscillation physical cross-linking for 1 day. After the cross-linking was completed, the outer layer of the vascular stent was electrospun continuously, and the PLCL solution prepared in step 1) was electrospun, and the outer layer flow rate of the blood vessel was 5.0 mL / h, the voltage was 10 kV, and the receiving distance was 15 cm. The receiver of the tubular stent was a stainless steel rod with a diameter of 5 mm. After the spinning was completed, the tube was removed, and the vascular stent separated from the stainless steel rod was cross-linked again for 2 days. After the cross-linking was completed, the artificial blood vessel was placed in a vacuum drying oven for drying for 24-48 hours to obtain a double anti-calcification decellular matrix artificial blood vessel loaded with catS inhibitor cross-linked with baicalin.

[0077] Comparative Example 1

[0078] The blood vessels that have not been cross-linked with baicalin are prepared as follows:

[0079] (1) Preparation of decellularized matrix powder

[0080] The porcine thoracic aorta retrieved from the slaughterhouse was decellularized using a combination of hypertonic and hypotonic solutions, TritonX-100 and bio-enzymes, freeze-dried, ground into powder, and stored at -20°C for later use.

[0081] (2) Preparation of electrospinning solution

[0082] 1) Preparation of PLCL solution: 1.2 g of PLCL material was dissolved in 10 ml of hexafluoroisopropanol (HFIP), and the solution was stirred overnight on a magnetic stirrer to obtain a PLCL solution with a mass / volume concentration of 12%.

[0083] 2) Prepare a solution containing decellularized matrix powder: dissolve the decellularized matrix powder in the solution prepared in 1) to obtain a solution with a mass / volume concentration of 0.5%. Stir the solution on a magnetic stirrer for several hours and set aside.

[0084] 3) Weigh a certain amount of catS inhibitor and dissolve it in 2) to make the final drug concentration 50 mg / mL.

[0085] (3) Preparation of artificial vascular stent

[0086] The solution prepared in step 3) was electrospun, and the electrospinning conditions were: the inner layer flow rate of the vascular stent was 0.1 mL / h, the voltage was 6 kV, and the receiving distance was 8 cm; the outer layer of the vascular stent was electrospun continuously, and the PLCL solution prepared in step 1) was electrospun, the outer layer flow rate of the blood vessel was 1.0 mL / h, the voltage was 8 kV, and the receiving distance was 10 cm. The receiver of the tubular stent was a stainless steel rod with a diameter of 2 mm. After spinning, the tube was removed, and the artificial blood vessel was placed in a vacuum drying oven and dried for 24 hours to obtain an artificial blood vessel.

[0087] Comparative Example 2

[0088] No baicalin cross-linking treatment was performed and no cat S inhibitor was added.

[0089] The preparation process is as follows: solution 2) containing acellular matrix powder is subjected to electrospinning. The electrospinning conditions are: the inner layer flow rate of the vascular stent is 0.1 mL / h, the voltage is 6 kV, and the receiving distance is 8 cm; the outer layer flow rate of the blood vessel is 1.0 mL / h, the voltage is 8 kV, and the receiving distance is 10 cm. The receiver of the tubular stent is a stainless steel rod with a diameter of 2 mm. After spinning, the tube is removed and placed in a vacuum drying oven for 24 hours to obtain a control group artificial blood vessel containing only the decellularized matrix.

[0090] The performance of the materials prepared in the above examples and comparative examples was characterized as follows.

[0091] (1) Characterization infrared image of baicalin ( Figure 1 ). Baicalin was combined with the decellularized matrix by chemical cross-linking, and Fourier transform infrared spectroscopy detected that baicalin was successfully cross-linked to the vascular stent.

[0092] (2) Baicalin was loaded onto a vascular stent and the apatite deposition on the stent surface was evaluated using a simulated body fluid method. Figure 2 ). Blank is not cross-linked with baicalin, and more apatite is found (i.e., comparative example 1, as indicated by the white arrow); after the artificial vascular stent containing the decellularized matrix is ​​cross-linked in baicalin solutions of different concentrations, there is basically no apatite deposition. This indicates that the presence of baicalin on the stent makes it difficult for apatite to deposit. It is speculated that baicalin combines with the protein in the decellularized matrix, reducing the deposition sites of calcium ions, so that less apatite is deposited on the stent.

[0093] (3) The artificial vascular stent containing cat S inhibitor in Example 1 was cross-linked with baicalin and implanted subcutaneously in SD rats. After 2 months, the samples were taken for histological staining observation ( Figure 3 ).

[0094] (4) Subcutaneous implantation of animals was performed and frozen sections were obtained. Von Kossa staining was used to observe the calcification. Figure 4 , where the dotted line and arrow indicate the calcification position). The results show that compared with the comparative example 2 without baicalin cross-linking treatment and without adding cat S inhibitor (i.e. Figure 4 The stent was treated with cat S inhibitor and baicalin (i.e. Figure 4 The scaffold materials prepared in Example 2 and Example 3 also have similar properties to Example 1, and will not be described in detail.

[0095] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, they are also intended to be included.

Claims

1. A small-caliber artificial blood vessel with dual anti-calcification properties, characterized in that: Along the inner diameter direction of the blood vessel, from inside to outside, it includes: an anti-calcification functional layer and a structural support functional layer; The anti-calcification functional layer is prepared by electrospinning a solution containing a basic material, wherein the solution containing the basic material contains acellular matrix powder and a cathepsin S inhibitor; The structural support functional layer is prepared by electrostatically spinning a solution containing a basic material; The anti-calcification functional layer and the structural support functional layer are both loaded with baicalin by physical cross-linking; The method for preparing the dual anti-calcification small-caliber artificial blood vessel comprises the following steps: S1. Solution preparation The basic material is dissolved in a solvent to prepare system one; the decellularized matrix powder is added to system one to prepare system two; Adding cathepsin S inhibitor to system 2 to prepare solution 1 containing basic materials; Adding baicalin to the solvent to prepare system three; S2. Preparation of artificial vascular stent The solution containing the basic material is electrospinned to prepare the inner layer of the vascular stent; the inner layer of the vascular stent is placed in the system three, shaken, and physically cross-linked to prepare the anti-calcification functional layer; On the outside of the anti-calcification functional layer, the system one is used to prepare the outer layer of the vascular stent by electrospinning to obtain a stent precursor, and the stent precursor is placed in the system three, shaken, and physically cross-linked to prepare a structural support functional layer, thereby completing the preparation of the dual anti-calcification small-caliber artificial blood vessel.

2. The small-caliber artificial blood vessel with dual anti-calcification properties according to claim 1, characterized in that: The base material in the first solution containing a base material and the base material in the second solution containing a base material are both poly-L-lactide-caprolactone.

3. The method for preparing a small-caliber artificial blood vessel with dual anti-calcification properties according to claim 1, characterized in that: The following steps are involved: S1. Solution preparation The basic material is dissolved in a solvent to prepare system one; the decellularized matrix powder is added to system one to prepare system two; Adding cathepsin S inhibitor to system 2 to prepare solution 1 containing basic materials; Adding baicalin to the solvent to prepare system three; S2. Preparation of artificial vascular stent The solution containing the basic material is electrospinned to prepare the inner layer of the vascular stent; the inner layer of the vascular stent is placed in the system three, shaken, and physically cross-linked to prepare the anti-calcification functional layer; On the outside of the anti-calcification functional layer, the system one is used to prepare the outer layer of the vascular stent by electrospinning to obtain a stent precursor, and the stent precursor is placed in the system three, shaken, and physically cross-linked to prepare a structural support functional layer, thereby completing the preparation of the dual anti-calcification small-caliber artificial blood vessel.

4. The preparation method according to claim 3, characterized in that: In system 1, the solvent was hexafluoroisopropanol and the mass / volume concentration of the base material was 12%; In system 2, the mass / volume concentration of the decellularized matrix powder was 0.5-5%; In the solution 1 containing the base material, the concentration of the cathepsin S inhibitor is 50-500 mg / mL; In system three, the solvent is hexafluoroisopropanol, and the concentration of baicalin is 0.5-5.0 mg / mL.

5. The preparation method according to claim 3, characterized in that: When preparing the inner layer of the vascular stent, the electrospinning conditions are: the flow rate of the inner layer of the vascular stent is 0.1-4.0 mL / h, the voltage is 6-15 kV, and the receiving distance is 8-20 cm.

6. The preparation method according to claim 3, characterized in that: When preparing the outer layer of the vascular stent, the electrospinning conditions are: the flow rate of the outer layer of the vascular stent is 1.0-6.0 mL / h, the voltage is 8-15 kV, and the receiving distance is 10-20 cm.

7. The preparation method according to claim 3, characterized in that: The inner layer of the vascular stent is placed in system three, and the physical cross-linking time is 1-2 days.

8. The preparation method according to claim 3, characterized in that: The scaffold precursor is placed in system three, and the physical cross-linking time is 1-2 days.

9. The preparation method according to claim 3, characterized in that: After the structural support functional layer is prepared, it is placed in a vacuum drying oven and dried for 24-48 hours.

Citation Information

Patent Citations

  • Therapy targeting cathepsin S

    CN101466736A

  • Biological compound artificial blood vessel and application

    CN109498839A

  • Novel dual-layer nerve conduit and preparation method thereof

    CN111214709A

  • Decellularized small intestinal submucosa / polylactic acid-glycolic acid copolymer composite scaffold as well as preparation method and application thereof

    CN112891634A

  • Scaffolds fabricated from electrospun decellularized extracellular matrix

    US20190142998A1